Cancer market commentary: 3 highlights from ESMO (Part 1)
AstraZeneca, breast, cancer, ESMO, Faslodex, kantar, Lynparza, Oncology, ovarian, pharma, treatment
0 Comment
Commentary on key cancer data from ESMO by Stephanie Hawthorne